General Information

Stock Quote

ABMD (Common Stock)
Exchange NASDAQ (US Dollar)
Price   $60.37
Change (%)   Stock is Down  0.20  (0.33%)
Volume   255,800
Data as of 05/29/15 11:40 AM ET
Minimum 20 minute delay
Refresh quote

Corporate Profile

Abiomed (NASDAQ: ABMD) is a global technology leader focused on RECOVERING HEARTS AND SAVING LIVES.

Abiomed CEO, Chairman, and President, Michael R. Minogue, has focused the company’s efforts on developing ground-breaking technologies designed to assist or replace the life-sustaining pumping function of the failing heart. The Company’s portfolio of products and services offer healthcare professionals an array of choices across a broad clinical spectrum. From the world’s first total replacement heart to the World’s Smallest Heart Pump, 1/100th the size of the heart with rapid and simple insertion, Abiomed is dedicated to finding ways to bring the most advanced and beneficial technology to patients and physicians.

More>>

More »   Recent News

Date Title  
05/05/15

DANVERS, Mass., May 5, 2015 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today reported fiscal fourth quarter 2015 revenue of $67.6 million, up 34% compared to revenue of $50.4 million in the same period of fiscal 2014, and a fiscal fourth quarter 2015 GAAP net income of $98.9 milli...

04/30/15

DANVERS, Mass., April 30, 2015 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Robert L. Bowen, Vice President & Chief Financial Officer, will present at the Deutsche Bank 40th Annual Health Care Conference on Thursday, May 7, 2015 at 2:10 p.m. ET. The conference w...

04/21/15

DANVERS, Mass., April 21, 2015 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD) announced today that on Tuesday, May 5, 2015, the Company will release financial results for the fourth quarter of fiscal 2015. The Company will host a conference call to discuss the results on Tuesday, May 5, 2015, at 8:00 a.m. EDT. Michael R. Minogue, Chairman, Preside...

03/23/15

Impella 2.5 is the Only FDA-Approved Percutaneous Hemodynamic Support Device Determined to be Safe and Effective for the High Risk PCI Indication DANVERS, Mass., March 23, 2015 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that it has received U.S. Food and Drug A...

02/25/15

DANVERS, Mass., Feb. 25, 2015 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Robert L. Bowen, Vice President & Chief Financial Officer, will present at the Cowen and Company 35th Annual Health Care Conference on Wednesday, March 4, 2015 at 11:20 a.m. EST. The conf...